NAT patients with disease recurrence or death due to pancreatic cancer within 12 months postoperatively (n = 37) exhibited higher CRP (p = 0.002) and CA19-9 levels (p < 0.001) than patients with no recurrence (Supplementary Table 3). This evidence concerns the gene CRP and pancreatic neoplasm.